The biotechnology era started when researchers discovered that they could freely access DNA and create predictable recombinant molecules. For Promega, that era started by offering quality restriction enzymes that could cut DNA in specific ways. That early work in enzyme production was the cornerstone to quality that now allows Promega to offer Current Good Manufacturing Practice (cGMP) enzymes for use in clinical diagnostic assays.
Building on internal transcription and translation capabilities, Promega expanded the tools available to our customers including: coupled transcription and translation systems, amplification systems (PCR), DNA sequencing, and other tools for genomics and cell biology research. Some of these tools were applied to solve specific unmet needs in civil society including forensic human identification.
In addition to the fundamental in vitro tools and applications, Promega pioneered the applied use of bioluminescence enabling high-throughput live-cell analytics. Drug discovery customers adopted Promega technology in reporter gene and cell viability assays as the gold standard in drug candidate screening. Oncology, infection, inflammation, neurodegenerative, and rare disease research segments each have examples of drugs developed using Promega bioluminescent technologies in the discovery process. In recent years this technology has greatly enhanced the development of new biologic based drugs for cancer treatment. Promega cellular analysis products have become so successful that many pharmaceutical companies now partner directly with Promega to create individually customized solutions for their unique needs.
Because of high-quality, reliable "tool kits" at their disposal, researchers have more freedom to focus on specific questions at the forefront of scientific discovery or clinical practice. The result is better science, using better tools, for faster answers.
Download Product Reach
PDF (725 KB)